You are here

Characterising cognitive impairments in patients with neuromyelitis optica spectrum disorder

Description 
Approximately 55% of patients with neuromyelitis optica spectrum disorder show cognitive impairment as evaluated using the Rao Brief Repeatable Neuropsychological Battery. Using well validated ocular motor and conventional nueropsychological assssments, this study aims to determine whether cognitive changes are consistent across the spectrum or whether they are differentially affected in patients who have myelin oligodendrocyte glycoprotein (MOG) antibodies, aquaporin-4 (AQP4) antibodies, or seronegativity for both antibodies.
Essential criteria: 
Minimum entry requirements can be found here: https://www.monash.edu/admissions/entry-requirements/minimum
Keywords 
neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein (MOG) antibodies, aquaporin-4 (AQP4) antibodies, cognitive dysfunction
School 
Central Clinical School » Medicine - Alfred
Available options 
PhD/Doctorate
Masters by research
Honours
Time commitment 
Full-time
Top-up scholarship funding available 
No
Physical location 
Alfred Centre
Co-supervisors 
Prof 
Owen White
Dr 
Meaghan Clough

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.